Heather Losey, Ph.D., Director, Program Lead in Immuno-Oncology and Jared Lopes, Ph.D., Principal Scientist – Alkermes discusses New Preclinical Data…
Browsing: Colorectal
Jeffrey A. Meyerhardt, MD, MPH, FASCO – Dana-Farber Cancer Institute discusses Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil,…
Jeffrey A. Meyerhardt, MD, MPH, FASCO – Dana-Farber Cancer Institute discusses Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil,…
Liv Johannessen, P.h.D.Syros Pharmaceuticals discusses Activity of SY-5609 an oral noncovalent potent and selective CDK7 inhibitor in preclinical models of…
Liv Johannessen, P.h.D. Syros Pharmaceuticals discusses Activity of SY-5609 an oral noncovalent potent and selective CDK7 inhibitor in preclinical models…
Marwan Fakih, MD of City of Hope discusses CodeBreak 100: activity of AMG 510, a novel small molecule inhibitor of…
Marwan Fakih, MD of City of Hope discusses CodeBreak 100: activity of AMG 510, a novel small molecule inhibitor of…
Andre Thierry, MD of University Pierre et Marie Curie @UPMC discusses pembrolizumab vs. chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic…
Andre Thierry, MD of University Pierre et Marie Curie @UPMC discusses pembrolizumab vs. chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic…
Earn CME: https://www.naccme.com/program/19-gdugi-1 In this webcast from the ‘Metastatic Colorectal Cancer: An individualized Approach to Optimal Treatment Selection and Adverse…
David Spetzler, MS of Caris Life Sciences @carisls discusses the MI FOLFAXai: how information is generated. A leading molecular science…
David Spetzler, MS of Caris Life Sciences @carisls discusses the MI FOLFAXai. A leading molecular science innovator focused on delivering…
A leading molecular science innovator focused on delivering on the promise of precision medicine, today announced the launch of MI…
Heinz-Josef Lenz, MD Professor of Medicine and Preventive Medicine Associate Director, Clinical Sciences J Terrence Lanni Chair in Cancer Research…
Earn CME: https://www.naccme.com/program/19-gdugi-1 In this webcast from the ‘Metastatic Colorectal Cancer: An individualized Approach to Optimal Treatment Selection and Adverse…
Earn CME: https://naccme.com/program/19-gdugi-1 In this webcast from the ‘Metastatic Colorectal Cancer: An individualized Approach to Optimal Treatment Selection and Adverse…
Katherine Clifton @katherineclift4 of @WUSTL answers a common question regarding using an anti-EGFR resistance mechanism: are these gene fusions targetable?…
Katherine Clifton, MD @katherineclift4 of @WUSTL discusses actionable fusions as an anti-EGFR resistance mechanism. __________ Read here:Â https://ascopubs.org/doi/10.1200/PO.19.00141
Scott Kopetz, MD @skopetz of @MDAndersonNews discusses what’s next for the phase 3 BEACON trial in colorectal cancer. __________ Pfizer…
Scott Kopetz, MD @skopetz of @MDAndersonNews explains the phase 3 BEACON CRC trial. ______ Pfizer Inc. (NYSE: PFE) today announced…
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3 BEACON CRC…
Sudha Amarnath, MD of Cleveland Clinic discusses how this will affect treatment and clinicians today. _____ Preoperative pelvic radiation (XRT),…
Sudha Amarnath, MD of Cleveland Clinic answers: Is this truly safe? Are these outcomes real? _____ Preoperative pelvic radiation (XRT),…
Sudha Amarnath, MD of Cleveland Clinic discusses toxicity and efficacy outcomes of preoperative pelvic radiation therapy in patients with inflammatory…
Afsaneh Barzi, MD of Keck School of Medicine discusses the factors to consider in the IDEA collaboration.
Afsaneh Barzi, MD of Keck School of Medicine provides the impact the IDEA data will have on clinicians.
Afsaneh Barzi, MD of Keck School of Medicine explains IDEA collaboration findings in 3 versus 6 months for stage 3…
Afsaneh Barzi, MD of Keck School of Medicine presents the IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration which investigated…
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center discusses the…
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center addresses molecular…
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center shares the…
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center addresses whether…
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center evaluates the…
Anders Rabbe CEO Of Isofol Medical Discusses Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS…
Anders Rabbe CEO Of Isofol Medical Discusses Arfolitixorin: Support From FDA, Doctors Are Excited About The Drug & How It…
Anders Rabbe CEO Of Isofol Medical Discusses Arfolitixorin: Increases Efficacy Of Standard Of Care Chemotherapy.
Alexa Schrock PhD Of Foundation Medicine Discusses How To Act On TMB Score: Patients Might Need A Higher TMB To…
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of…
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of…
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of…
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of…
John Strickler, M.D. Assistant Professor Of Medicine At Duke Cancer Institute, Discusses The Importance Of Genomic Profiling In Treating Colorectal…
Raymond Wadlow, M.D. Medical Oncologist At Inova Fairfax Hospital Discusses Thoughts On CCTG CO.26 Canadian Study Demonstrating Immunotherapy Benefit In…
Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health…
Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health…
Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health…
Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health…
Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health…
Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Whether Regorafenib…